Lexicon Pharmaceuticals (LXRX) Key Ratios

$2.24

up-down-arrow $-0.02 (-0.88%)

As on 04-Sep-2026 16:05EDT

Market cap

info icon

$997 Mln

Revenue (TTM)

info icon

$41 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

5.7

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -96.72 -97.60 -29.03 366.68 42.35
EBIT -5,431.99 -623.63 46.51 16.42 -205.26
Net Profit -2,946.50 -1,077.09 49.33 15.29 -209.92
EPS -2,685.99 -911.66 54.11 21.10 -183.09
Book Value -- -- -26.71 -21.88 -25.37
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -4,941.45-23,255.52-127.16-84.34-594.65
Net Margin info ---13,095.04-147.38----
Return on equity info -125.29-105.85-43.34-39.72-167.66
Return on Capital info -69.15-67.95---23.74-88.38
Return on Assets info -60.12-58.69-23.27-20.83-75.93
Debt to Equity (x) info ----0.290.580.74
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
--
-23.74
-88.38
-95.33
-70.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-43.34

Lower than Peers by 2.94

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
-43.34
-39.72
-167.66
-168.50
-88.37
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-23.27

Higher than Peers by 7.70

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
-23.27
-20.83
-75.93
-83.60
-61.56
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-127.16

Lower than Peers by 43.54

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
-127.16
-84.34
-594.65
-14,145.35
-72,273.38
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-147.38

Lower than Peers by 54.71

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
-147.38
-101.08
-644.78
-14,710.88
-5,875.73
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

-29.03

Lower than Peers by 82.98

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
-29.03
0.60
24.81
7.66
-0.53
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

46.51

Higher than Peers by 47.31

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
46.51
77.27
-8.52
-69.53
-15.53
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

49.33

Higher than Peers by 56.63

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
49.33
74.88
-13.15
-73.74
-16.16
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

54.11

Higher than Peers by 39.46

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
54.11
0.75
0.23
-0.34
0.08
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

12.01

Higher than Peers by 22.18

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
12.01
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.29

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
0.29
0.58
0.74
1.14
0.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
0.01
0.06
0.01
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

13.37

Higher than Peers by 7.56

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
13.37
4.88
5.44
5.60
6.08
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

13.29

Higher than Peers by 7.59

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
13.29
4.87
5.44
5.58
6.08
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-6.29

Lower than Peers by 4.20

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
-6.29
-5.04
-11.86
-13.00
-36.14
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

3.96

Lower than Peers by 15.18

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
3.96
4.79
11.17
83.89
20.14
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.16

Higher than Peers by 0.09

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
0.16
0.21
0.12
0.01
0.00
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
--
21.48
26.34
157.45
55.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
--
341.26
181.44
1.18
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
--
11,919.95
8,653.93
76.75
67.97
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
--
-11,557.21
-8,446.15
81.87
-12.79
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
--
-8.30
-1.33
-2.12
-3.54
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

5.71

Higher than Peers by 0.53

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
5.71
3.89
1.83
4.02
3.08
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

16.57

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
16.57
-9.28
-0.75
-1.83
-2.77
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

997

Higher than Peers by 851

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Lexicon Pharmaceuticals (LXRX)
997
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...